Founded in 2024, with a current fund size of 66M USD, Beiley BioFund is a prominent life sciences venture capital firm that works closely with industry innovators to create cutting-edge medications and technologies. Our primary focus is on developing inventive therapeutics that meet unfulfilled medical needs. We adopt a proactive stance in identifying teams focused on developing impactful treatments, aiding in crafting efficient development strategies to make these therapies accessible to patients.
Deal activity and portfolio updates would appear here
Connect your data source to see recent transactions